The article reviews the efficacy of chelation therapy in cardiovascular disease, particularly following myocardial infarction (MI), and highlights the potential benefits observed in specific subgroups, such as diabetic patients. It discusses findings from the Trial to Assess Chelation Therapy (TACT), which suggested some reduction in cardiovascular events but acknowledged the
